Andersen-Tawil syndrome (patient information): Difference between revisions
No edit summary |
|||
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{VKG}} | ||
==Overview== | ==Overview== | ||
| Line 9: | Line 9: | ||
==What Causes Andersen–Tawil syndrome?== | ==What Causes Andersen–Tawil syndrome?== | ||
Genes involved in the pathogenesis of Andersen-Tawil syndrome include ''KCNJ2'' gene, ''KCNJ5'' gene and an unknown gene. | Genes involved in the pathogenesis of Andersen-Tawil syndrome include the ''KCNJ2'' gene, ''KCNJ5'' gene and an unknown gene. | ||
==Who is at Highest Risk?== | ==Who is at Highest Risk?== | ||
| Line 27: | Line 27: | ||
==Prevention== | ==Prevention== | ||
Effective measures for the primary prevention of [[Andersen-Tawil syndrome]] ([[Andersen-Tawil syndrome|ATS]]) include [[lifestyle]] modifications, [[carbonic anhydrase inhibitors]] using, [[potassium]] supplements and [[cardioverter-defibrillator]].Effective measures for the secondary prevention of Andersen-Tawil syndrome (ATS) include avoidance of some antiarrhythmic drugs and anesthetic precautions. | |||
==What to Expect (Outlook/Prognosis)?== | ==What to Expect (Outlook/Prognosis)?== | ||
[[Prognosis]] is generally range from good to poor. | |||
==Possible Complications== | ==Possible Complications== | ||
Common [[complications]] of [[Andersen-Tawil syndrome]] include [[neuromuscular]] [[Symptom|symptoms]] and [[malignant hyperthermia]]. | |||
==Sources== | ==Sources== | ||
Latest revision as of 19:14, 17 February 2020
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]
Overview
Andersen–Tawil syndrome may be classified according to genetic mutations into two groups: Type 1 Andersen–Tawil syndrome and type 2 Andersen–Tawil syndrome.
What are the Symptoms of Andersen–Tawil syndrome?
The most common symptoms of Andersen-Tawil Syndrome include periodic paralysis, ventricular arrhythmias, syncope, muscular weakness, developmental abnormalities, sudden cardiac death and seizures.
What Causes Andersen–Tawil syndrome?
Genes involved in the pathogenesis of Andersen-Tawil syndrome include the KCNJ2 gene, KCNJ5 gene and an unknown gene.
Who is at Highest Risk?
Patients with KCNJ2 gene, KCNJ5 gene mutations.
Diagnosis
The diagnosis of Andersen-Tawil syndrome (ATS) is suspected in individuals whose satisfies either criteria A and criteria B with molecular genetic testing to confirm.
When to Seek Urgent Medical Care?
When the patient experiences intermittent muscular weakness, syncope, and periodic paralysis.
Treatment Options
There is no treatment for Andersen-Tawil Syndrome; the mainstay of therapy is to treat the symptoms and manage the patient. Potassium levels play an important role in the management of the symptoms.
Where to find Medical Care for (Disease name)?
Medical care for (disease name) can be found here.
Prevention
Effective measures for the primary prevention of Andersen-Tawil syndrome (ATS) include lifestyle modifications, carbonic anhydrase inhibitors using, potassium supplements and cardioverter-defibrillator.Effective measures for the secondary prevention of Andersen-Tawil syndrome (ATS) include avoidance of some antiarrhythmic drugs and anesthetic precautions.
What to Expect (Outlook/Prognosis)?
Prognosis is generally range from good to poor.
Possible Complications
Common complications of Andersen-Tawil syndrome include neuromuscular symptoms and malignant hyperthermia.